SEC Form 4 · accession 0001225208-17-002699
Merck & Co., Inc. · MRK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patricia F Russo
Director
Period of report
Feb 8, 2017
Accepted (ET)
Feb 9, 2017 · 12:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000310158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 8, 2017 | M | 5,000 | $35.19 | A | 18,148 | D | |
| Common StockF1 | Feb 8, 2017 | S | 5,000 | $64.4242 | D | 13,148 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $35.19 | Feb 8, 2017 | M | 5,000 | D | Aug 4, 2011 | Aug 3, 2020 | Common Stock | 5,000 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.4200 to $64.4284, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F2The option became exercisable in equal installments on 8/4/2011, 8/4/2012 and 8/4/2013.